Wells Fargo & Company Tyme Technologies, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	BUY	$0.23 - $0.35 $473 - $720	2,058 Added 13.27%	17,565 $5,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $0 - $1	2 Added 0.01%	15,507 $5,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.04 $0 - $1	1 Added 0.01%	15,505 $9,000
Q3 2021 Nov 15, 2021	BUY	$0.99 - $1.38 $28 - $40	29 Added 0.19%	15,504 $16,000
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $26,142 - $42,882	-22,932 Reduced 59.71%	15,475 $20,000
Q1 2021 May 13, 2021	SELL	$1.34 - $3.53 $107,813 - $284,016	-80,458 Reduced 67.69%	38,407 $69,000
Q4 2020 Feb 09, 2021	SELL	$0.87 - $1.26 $66,272 - $95,980	-76,175 Reduced 39.06%	118,865 $145,000
Q3 2020 Nov 05, 2020	SELL	$0.93 - $1.35 $2,580 - $3,746	-2,775 Reduced 1.4%	195,040 $191,000
Q2 2020 Aug 13, 2020	BUY	$0.97 - $1.7 $114,788 - $201,176	118,339 Added 148.9%	197,815 $263,000
Q1 2020 May 14, 2020	BUY	$0.9 - $1.95 $71,528 - $154,978	79,476 New	79,476 $88,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.